Keith Orford, insider at Calithera Biosciences

Keith Orford Insider Information

Dr. Orford is Chief Medical Officer. Since joining Calithera in 2015, he has overseen clinical development activities, including Clinical Operations and Medical Affairs. Prior to joining Calithera, Dr. Orford was the Clinical Development Lead in the Immuno-Oncology and Combinations Development Performance Unit at GlaxoSmithKline, where he oversaw the clinical activities on multiple early stage clinical trials with targeted agents and novel immune-based therapies. Prior to GlaxoSmithKline, Dr. Orford was at Merck, where he worked on early clinical development programs across oncology and other therapeutic areas. Previously, Dr. Orford was a Research Fellow and Instructor at Massachusetts General Hospital and Harvard Medical School, where he completed clinical training in Internal Medicine, as well as postdoctoral work studying the epigenetic regulation of hematopoietic and embryonic stem cell differentiation. Dr. Orford received his undergraduate, M.D., and Ph.D. degrees from Georgetown University.

What is Keith Orford's net worth?

The estimated net worth of Keith Orford is at least $44,700.00 as of May 22nd, 2019. Dr. Orford owns 10,000 shares of Calithera Biosciences stock worth more than $44,700 as of August 16th. This net worth approximation does not reflect any other investments that Dr. Orford may own. Learn More about Keith Orford's net worth.

What is Keith Orford's salary?

As the Director of Calithera Biosciences, Inc., Dr. Orford earned a total compensation package of $1,372,586.00 in 2021. Dr. Orford earned a salary of $416,101.00, a bonus of $56,568.00, stock awards of $551,300.00, options awards of $324,990.00, and other compensation of $23,627.00. Learn More on Keith Orford's salary.

How do I contact Keith Orford?

The corporate mailing address for Dr. Orford and other Calithera Biosciences executives is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. Calithera Biosciences can also be reached via phone at (650) 870-1000 and via email at [email protected] Learn More on Keith Orford's contact information.

Has Keith Orford been buying or selling shares of Calithera Biosciences?

Keith Orford has not been actively trading shares of Calithera Biosciences in the last ninety days. Most recently, Keith Orford sold 48,190 shares of the business's stock in a transaction on Thursday, November 11th. The shares were sold at an average price of $0.88, for a transaction totalling $42,407.20. Learn More on Keith Orford's trading history.

Who are Calithera Biosciences' active insiders?

Calithera Biosciences' insider roster includes Susan Molineaux (CEO), and Keith Orford (Director). Learn More on Calithera Biosciences' active insiders.

Are insiders buying or selling shares of Calithera Biosciences?

During the last twelve months, Calithera Biosciences insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $85,000.00. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 100,000 shares worth more than $85,927.60. The most recent insider tranaction occured on November, 11th when Director Keith Orford sold 48,190 shares worth more than $42,407.20. Insiders at Calithera Biosciences own 6.6 % of the company. Learn More about insider trades at Calithera Biosciences.

Information on this page was last updated on 11/11/2021.

Keith Orford Insider Trading History at Calithera Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/11/2021Sell48,190$0.88$42,407.20View SEC Filing Icon  
11/9/2021Sell51,810$0.84$43,520.40View SEC Filing Icon  
12/16/2020Sell2,447$6.00$14,682.00View SEC Filing Icon  
6/17/2019Sell417$6.00$2,502.00View SEC Filing Icon  
5/22/2019Sell416$6.00$2,496.0010,000View SEC Filing Icon  
4/15/2019Sell416$6.33$2,633.2810,416View SEC Filing Icon  
3/15/2019Sell417$6.43$2,681.3110,832View SEC Filing Icon  
3/11/2019Sell1,565$6.00$9,390.00View SEC Filing Icon  
10/15/2018Sell313$6.05$1,893.6510,314View SEC Filing Icon  
10/11/2018Sell1,252$6.00$7,512.00View SEC Filing Icon  
7/17/2017Sell2,120$18.31$38,817.20View SEC Filing Icon  
See Full Table

Keith Orford Buying and Selling Activity at Calithera Biosciences

This chart shows Keith Orford's buying and selling at Calithera Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Calithera Biosciences Company Overview

Calithera Biosciences logo
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $4.47
Low: $3.68
High: $4.47

50 Day Range

MA: $4.21
Low: $2.41
High: $55.00

2 Week Range

Now: $4.47
Low: $2.30
High: $49.80


220,180 shs

Average Volume

134,349 shs

Market Capitalization

$21.73 million

P/E Ratio


Dividend Yield